Gabrielle_20
2021-09-01
๐๐๐
Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19
ๅ ่ดฃๅฃฐๆ๏ผไธ่ฟฐๅ ๅฎนไป ไปฃ่กจๅๅธไบบไธชไบบ่ง็น๏ผไธๆๆๆฌๅนณๅฐ็ไปปไฝๆ่ตๅปบ่ฎฎใ
ๅไบซ่ณ
ๅพฎไฟก
ๅคๅถ้พๆฅ
็ฒพๅฝฉ่ฏ่ฎบ
ๆไปฌ้่ฆไฝ ็็็ฅ็ผ่งๆฅๅกซ่กฅ่ฟ็็ฉบ็ฝ
ๆๅผAPP๏ผๅ่กจ็ๆณ
APPๅ ๆๅผ
ๅ่กจ็ๆณ
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":816636257,"tweetId":"816636257","gmtCreate":1630494375579,"gmtModify":1631890641221,"author":{"id":3569531614182731,"idStr":"3569531614182731","authorId":3569531614182731,"authorIdStr":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>๐๐๐</p></body></html>","htmlText":"<html><head></head><body><p>๐๐๐</p></body></html>","text":"๐๐๐","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/816636257","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the worldโs most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck & Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck & Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"้ปๆฒไธ","XLV":"ๅฅๅบท็ งๆค็ฑป่กETF-SPDR"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/816636257"}
็ฒพๅฝฉ่ฏ่ฎบ